Biologic Therapies IV
IL6 Targeting
 |
||
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: June 10, 2011
Expiration Date: June 10, 2013
Estimated Time of Completion: 30 minutes
Description
Biologic Therapies IV: Webcast Series is a compilation of live presentations recorded at the Biologic Therapies Summit IV: Current and Emerging Indications. This webcast series continues a successful tradition of presenting innovative, quality presentations that provide evidence-based, practical knowledge to fulfill participants' educational objectives. An international faculty of experts who span a multitude of scientific disciplines will provide their insights on a variety of timely topics, including the following:
- Research advances in immunodeficiencies and autoimmunity,
- Approved biologic agents and clinical trial data,
- Development of new biologic agents,
- Toxicities associated with biologic agents,
- Clinical implications and potential new indications.
Learning Objectives
- Describe recent data concerning the efficacy and safety of IL-6 inhibition in rheumatoid arthritis.
- Identify the risks and benefits of IL-6 inhibition in patients with rheumatic diseases.
Target Audience
This activity is directed to rheumatologists, gastroenterologists, dermatologists, pulmonologists, internal medicine physicians, nurse practitioners, physician assistants, and other health care professionals interested in or using biologic therapies in autoimmune and inflammatory disorders.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director
Leonard Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Orthopaedic & Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Faculty
Arthur Kavanaugh, MD
Professor of Medicine
Director
Center for Innovative Therapy
Division of Rheumatology, Allergy, and Immunology
University of California, San Diego
San Diego, CA
Disclosures
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated that he may have a relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:
| Leonard Calabrese, DO | ||
| Consulting: |
BMS; Elan Pharmaceuticals, Inc; Wyeth |
|
| Consulting, Teaching & Speaking: |
Abbott Laboratories; Amgen; Centocor; Genentech/Roche; Pfizer |
|
The following faculty has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:
Arthur Kavanaugh, MD
The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational
grants for partial support of this activity from:
Abbott Laboratories Inc.,
Amgen, Inc.,
Bristol-Myers Squibb,
Centocor Ortho Biotech Services, LLC,
Genentech, Inc. and Biogen Idec,
UCB, Inc.
This CME activity was produced by The Cleveland Clinic Foundation Center for Continuing Education and the
R.J. Fasenmyer Center for Clinical Immunology.
